Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

NCT02355535 is registered in ClinicalTrials.gov with Vanquish Oncology, Inc. as lead sponsor.

NCT NCT02355535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02355535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Lead sponsor
Vanquish Oncology, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2015
Completion date
May 18, 2020
Enrollment
48 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors, pancreatic neuroendocrine tumor, solid tumor